[Translation] A randomized, single-blind, positive-drug parallel-controlled, multicenter clinical trial of intravenous human immunoglobulin (pH4) in the treatment of primary immune thrombocytopenia
以已上市静注人免疫球蛋白(pH4)为对照,评价新疆德源生物工程有限公司研制开发的静注人免疫球蛋白(pH4)治疗原发免疫性血小板减少症的有效性和安全性
[Translation] To evaluate the efficacy and safety of intravenous human immunoglobulin (pH4) developed by Xinjiang Deyuan Bioengineering Co., Ltd. in the treatment of primary immune thrombocytopenia, using the marketed intravenous human immunoglobulin (pH4) as a control.